Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Stock Information for OncoSec Medical Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OncoSec Medical Incorporated

Amneal to Participate at the 2023 Jefferies Healthcare Conference
Amneal Launches Third Biosimilar with FYLNETRA(TM) (pegfilgrastim-pbbk) in the United States
Amneal Reports First Quarter 2023 Financial Results
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
Amneal to Report First Quarter 2023 Results on May 5, 2023
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.